Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00719862 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies
A Phase 3 study, sponsored by Meda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 481
- Enrollment target
NCT00719862 is a Phase 3 study that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 481 participants.
The verdict
NCT00719862, a Phase 3 study, has completed, sponsored by Meda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 481 participants
- Enrollment target
Study Summary
The Purpose of this study is to determine if one allergy medication (0.15% azelastine hydrochloride) is more effective than Placebo alone
Interventions
- DRUG Placebo nasal spray
- DRUG 0.15% azelastine hydrochloride Nasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 481 participants |
| Start Date | 2007-08 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00719862
The ClinicalTrials.gov registry entry for NCT00719862 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 481 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meda Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo nasal spray is the first listed.
NCT00719862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00719862 about?
NCT00719862 is a clinical study titled "A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies". The Purpose of this study is to determine if one allergy medication (0.15% azelastine hydrochloride) is more effective than Placebo alone
What is the current status of trial NCT00719862?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 481 participants. The study started on 2007-08. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00719862?
The interventions under investigation include: Placebo nasal spray (DRUG), 0.15% azelastine hydrochloride Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT00719862?
This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.